Gold clearly mentioned CMC issues on the May 9 CC, but he characterized them as relatively minor and east to fix. The new plaintiffs say otherwise. Whom are you gonna believe?
For what it’s worth, on IMCL’s 12/31/01 CC following the FDA’s Refusal-to-File letter for Erbitux, Sam Waksal told investors that the issues raised in the RTF letter were relatively minor and easy to fix. Regards, Dew
Market Data 
Markets 
AI
